Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01809171

Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients

Sponsor: Universitaire Ziekenhuizen KU Leuven

Conditions Breast Cancer Musculoskeletal Disease

Updated 6 times since 2017 Last updated: Oct 20, 2015 Started: Oct 31, 2013 Primary completion: Aug 31, 2015 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Inclusion problems

Other terminated trials from Universitaire Ziekenhuizen KU Leuven

See all terminations from Universitaire Ziekenhuizen KU Leuven

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

This PHASE2/PHASE3 trial investigates Breast Cancer and Musculoskeletal Disease and is currently terminated or withdrawn. Universitaire Ziekenhuizen KU Leuven leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Nov 2022 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Jan 2021 — Nov 2022 [monthly]

Terminated PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2_PHASE3

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Universitaire Ziekenhuizen KU Leuven

Data source: Universitaire Ziekenhuizen KU Leuven

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leuven, Belgium